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Purpose: Retinal degeneration (RD) is a complex mechanism that appears to involve many biologic processes including
oxidative stress, apoptosis, and cellular remodeling. Currently there are 51 mapped, but not identified, RD human disease
loci.
Methods: To assign possible disease genes to RD loci, we have used a comparative genomics procedure that incorporates
microarray gene expression data of three independent mouse models for photoreceptor dystrophy (rd1, rd2, and constant
light-damage in BALB/c mice), human ortholog data, and databases of known chromosomal locations involved in human
RD. Immunohistochemistry and enzyme activity assays were used to further characterize a candidate gene product.
Results: Our analysis yielded candidate genes for four mapped, but unsolved, human chromosomal locations and
confirmed two previously identified monogenic disease loci for human RD, thus validating our approach. PLA2G7
(phospholipase A2, group VII; PAF-AH, Lp-PLA2), a candidate for a dominant form macular dystrophy (Benign
Concentric Annular Macular Dystrophy [BCMAD]), was selected for further study. The PLA2G7 enzyme is known to
mediate breakdown of oxidatively damaged phospholipids, a contributor to oxidative stress in the retina. PLA2G7 protein
was enriched in mouse photoreceptor inner and outer segments. In the rd1, rd2, and BALB/c mice exposed to constant
light, retinal tissue activity levels, but not plasma levels, were significantly reduced at the onset of photoreceptor cell
death.
Conclusions: We have shown that this comparative genomics approach verified existing RD genes as well as identified
novel RD candidate genes. The results on the characterization of the PLA2G7 protein, one of the novel RD genes, suggests
that retinal tissue PLA2G7 levels may constitute an important risk factor for BCMAD. In summary, this reverse mapping
approach, using accepted mouse models of human disease and known human RD loci, may prove useful in identifying
possible novel disease candidates for RD and may be applicable to other human diseases.
The identification of genes and loci causing inherited
retinal diseases such as retinitis pigmentosa (RP), macular
degeneration (MD), and Usher (USH) syndrome are crucial
for disease management [1]. Inherited retinal degeneration
(RD) is the major cause of blindness in the developed world.
Retnet lists 28 different categories, and two complex forms of
retinal disease, including 191 loci that have been mapped; the
disease gene has been identified for 140 of these loci. While
great strides have been made to identify genes and mutations
causing these diseases, progress has been hampered by their
enormous complexity, due to genetic, allelic, phenotypic, and
clinical heterogeneity of patient populations [2]. For example,
autosomal dominant RP has been associated with mutations
in  16  genes  and  another  locus  with  the  gene  yet  to  be
determined; autosomal dominant macular degeneration has
been associated with mutations in 14 genes and eight other
loci; and autosomal recessive RP has been associated with
Correspondence to: Bärbel Rohrer, Department of Ophthalmology,
Medical  University  of  South  Carolina,  167  Ashley  Avenue,
Charleston,  SC,  29425;  Phone:  (843)  792-5086;  FAX:  (843)
792-1723; email: rohrer@musc.edu
mutations in 21 genes with five other loci. Thus, it is clear that
there are a good number of existing RD loci for which the
mutant genes are yet to be determined and, in addition, yet to
be discovered new loci for various monogenic and complex
RDs such as age-related macular degeneration (AMD) and
diabetic retinopathy.
We  propose  a  technique  to  identify  possible  gene
candidates  for  these  human  disease  loci:  gene  expression
analysis in mouse models of photoreceptor dystrophy. These
analyses could identify genes that are misregulated during
photoreceptor degeneration, correlating the human orthologs
with chromosomal locations associated with inherited human
retinal degeneration. Here we have followed this approach by
using gene expression analysis from three unrelated mouse
models of photoreceptor dystrophy. Two models match the
human condition, as the same gene functions are affected (the
rd1 and the rd2 mouse [3,4]) as well as a popular oxidative
stress model thought to be relevant for diseases such as AMD
(light-damage (LD) in albino mice [5]). The results are based
on the premise that information collected about the orthologs
of genes between species that exhibit the same trait or disease
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1639may be useful. Orthologs, by definition, evolved from the
same gene, and usually share the same function. Correlating
this  information  may  provide  evidence  to  determine  a
regulatory  pattern  of  orthologs  associated  with  congruent
traits [6]. Genes that matched to the human RD loci and that
were commonly up- or downregulated in all three models of
degeneration are thought to be good candidates, especially if
a  literature  search  suggests  that  the  known  biologic
information might be relevant to RD. Finally, as human retinal
degenerations are usually caused by missense or nonsense
mutations resulting in altered gene expression, the approach
using  expression  differences  to  identify  candidates  is
acceptable.
One  of  the  genes,  PLA2G7  (PAF-AH,  Lp-PLA2),  a
candidate for a dominant form of macular dystrophy, benign
concentric  annular  macular  dystrophy  (BCMAD),  was
selected  for  further  study.  The  main  function  of  platelet-
activating factor (PAF) acetylhydrolase is to convert PAF into
the biologically inactive lyso-PAF [7]. However, PLA2G7
also  hydrolyzes  oxidized  phospholipids.  Oxidized
phospholipids are known to initiate cell death, triggering the
intrinsic apoptotic caspase cascade [8]. Oxidative stress is
activated in the photoreceptors of the three models of retinal
degeneration studied herein [9] and is a contributing factor in
AMD  [10].  In  addition,  products  generated  by  PLA2G7,
lysophosphatidylcholine  and  oxidized  nonesterified  fatty
acids,  are  thought  to  contribute  to  inflammation  in
atherosclerosis,  coronary  artery  disease,  and  stroke  [11].
Plasma PLA2G7 activity levels can be used in these diseases
as a biomarker, while also functioning as an independent risk
predictor  for  cardiovascular  disease  [12].  Finally,
inflammation has been proposed as a possible driving force
of AMD pathology [13-18].
The reverse-mapping approach identified possible novel
disease candidates for RD, which are discussed in the context
of their known gene function and possible involvement in
disease pathology. Of the identified candidate genes, two of
them were previously confirmed to be the disease genes in loci
associated with photoreceptor degeneration, supporting the
validity of our approach while four additional genes were
novel candidates for three mapped RD chromosomal loci. One
of the candidate gene products, Pla2g7, was localized to the
mouse photoreceptor inner and outer segments, and retinal
tissue  activity  levels  were  significantly  reduced  before
photoreceptor cell death. Hence, this tactic has resulted in the
identification  of  novel  candidates  for  three  RD  loci  and
demonstrated this as a feasible approach to identifying gene
candidates for other human diseases as well.
METHODS
Animals: C57BL/6 rd1 [19] and rd2 [4] mice were gifts from
Drs. Debora Farber and Gabriel Travis (both at University of
California, Los Angeles, CA). Both strains were maintained
as homozygotes. C57BL/6 and BALB/c mice were generated
from  breeding  pairs  obtained  from  Harlan  Laboratories
(Indianapolis,  IN).  Animals  were  housed  in  the  Medical
University of South Carolina (MUSC) Animal Care Facility
under a 12 h:12 h light–dark cycle with access to food and
water ad libitum. The ambient light intensity at the eye level
of the animals was 85±18 lux. Light damage was produced by
exposing the BALB/c animals to constant fluorescent light for
24 or 48 h at an illuminance of approximately 1500 lux. This
intensity reduces the number of photoreceptors to 50% within
10 days in 3-month-old (young adult) albino mice [5]. All
experiments were performed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the University Animal Care
and Use Committee.
Microarray analyses:
Samples—Affymetrix  oligonucleotide  (MGU74AV2)
arrays (Affymetrix Inc, Santa Clara, CA), containing 12489
genes and ESTs, were used for this analysis as described
previously [20]. The Affymetrix CEL files, containing the raw
intensity values, were used for expression data analysis. To
determine genes that could be potential candidates for retina-
specific  chromosomal  locations,  we  compared  gene
expression data from the three unrelated mouse models of
photoreceptor  dystrophy.  To  analyze  genes  involved  in
neurodegeneration, we argued that genes altered early in the
progression would be involved in initiating degeneration. For
the rd1 mouse, we collected retinas from days P6 and P10,
which  represent  early  time  points  during  which  cGMP
continues to rise [3] and apoptosis is initiated [21]; for the
rd2  mouse,  we  collected  retinas  from  P14  and  P21,
representing  early  time  points  during  the  first  phase  of
apoptosis [21]; and finally for the light-damaged paradigm,
we collected retinas 24 and 48 h after the onset of constant
light at 1500 lux, a point at which a few TUNEL-positive
photoreceptors can be observed, but no cell loss can yet be
documented [9].
RNA isolation—All chemicals used in this study were at
least molecular biology grade material and purchased from
Fisher Scientific (Pittsburgh, PA), unless otherwise noted.
Animals (see Samples for ages of animals) were sacrificed by
decapitation  and  retinas  isolated  and  stored  in  RNA-later
(Ambion, Austin, TX) at −20 °C. Retinas from four animals
per genotype per time point were pooled, and each data point
was obtained in duplicate. Pooling is recommended as the
method of choice to reduce the number of arrays needed to
generate reliable data [20,22]. Total RNA was isolated using
Trizol  (Ambion),  followed  by  a  clean-up  using  RNAeasy
minicolumns (Qiagen, Valencia, CA). The quality of the RNA
was examined by gel electrophoresis, and spectrophotometry
[20].
Microarray  procedures—Sample  preparation  and
hybridization was performed as described in the Affymetrix
Expression  Analysis  Technical  Manual  and  published
previously  [20].  In  short,  double-stranded  cDNA  was
Molecular Vision 2008; 14:1639-1649 <http://www.molvis.org/molvis/v14/a194> © 2008 Molecular Vision
1640generated  (SuperScript™  II  Reverse  Transcriptase;
Invitrogen, Carlsbad, CA) using 5 μg total RNA as starting
material,  and  purified  using  phase-lock  gel  columns
(Eppendorf,  Westbury,  NY)  followed  by  ethanol
precipitation. The purified cDNA served as a template for the
generation  of  biotinylated  cRNA,  using  the  BioArray™
HighYield™ RNA transcript labeling kit (Enzo Diagnostics,
New  York,  NY).  Labeled  probes  were  purified  using  the
RNEasy  mini  kit  (Qiagen,  Valencia,  CA),  fragmented  by
metal-induced  hydrolysis  at  94  °C  for  35  min  (100  mM
potassium acetate, 30 mM magnesium acetate, and 40 mM
tris-acetate) and stored at -80 ºC. The length of the cRNA and
fragmentation was confirmed by agarose gel electrophoresis.
Hybridization with equal amounts of labeled cRNA (15 µg/
array) and readout was performed by the DNA Microarray
Core Facility at MUSC, using the Affymetrix Fluidics Station.
Data analysis:
Normalization and filtering—Genechips were scanned
using the Affymetrix scanner (Microarray Suite 5.0 software)
to obtain probe level data. Outputs were scaled to the same
target intensity. The raw Affymetrix data (absolute expression
level  and  perfect  match  (PM)-values)  was  used  for
normalization. Each of the three model sets were normalized
using quantile normalization on the probe and probe set level.
This procedure was done using Dchip software [23]. Gene
filtering  was  performed  individually  on  the  three  retinal
degeneration sets. Normalized data was filtered on significant
p-values (≤0.05) in fold change and difference of the means
between  experimental  and  age-matched  control  samples
(value of ≥100). With an estimated median expression level
of 90 this automatically excludes low-expressing genes. Venn
analysis was used to identify genes that localized to RD loci.
Analysis of retinal degeneration chromosomal loci—
For us to be able to match the differentially expressed mouse
genes to known chromosomal locations involved in retinal
degeneration, we needed human orthologs to these mouse
genes. The Affymetrix NetAffx Analysis Center was used to
obtain the human orthologs, as well as accession numbers and
chromosome  locations  for  all  genes.  The  list  of  human
ortholog locations was correlated with the 191 human retina-
specific  locations  currently  listed  in  RetNet,  to  determine
which locations were unknown and unsolved.
Gene  ranking  and  probability—To  determine  the
probability of one of the genes in our analysis falling into one
of the retina-related loci, we implemented an algorithm using
the gene lengths, locus lengths, and chromosome lengths.
Probability was determined by calculating the ratio of gene
length to locus length over the ratio of the gene length to
chromosome length. Genes were ranked based on a combined
score of probability: 5 (0%–4.9%), 4 (5%–9.9%), 3 (10%–
14.9%),  2  (15%–19.9%),  1  (20%-above).  This  score  was
multiplied by the number of models in which the genes were
differentially expressed (3, 2, or 1), resulting in a maximum
score of 15.
Gene ontology analysis—Gene Ontology (GO) analysis
on  the  identified  genes  was  done  using  GoStat  by  Tim
Beissbarth. GO p-values were computed, and the GO terms
with significant p-values identified to compile the final list of
overrepresented  GO  terms.  All  ontologies  (Molecular
Function, Biologic Process, and Cellular Component) were
analyzed as a group.
Pla2g7 analysis:
Immunohistochemistry—For  immunohistochemical
analysis, eyes were fixed in 4% paraformaldehyde, rinsed,
cryoprotected in 30% sucrose overnight, frozen in TissueTek
O.C.T. (Fisher Scientific) and cut into 14 μm cryostat sections.
Immunohistochemistry  was  performed  as  described
previously  [24]  using  an  anti-PAF-AH  antibody  (Lis-1;
Abcam,  Cambridge,  MA)  at  1:100.  For  visualization,  a
fluorescent-labeled  secondary  antibody  (Alexa  488;
Invitrogen,  Carlsbad,  CA)  was  used.  Each  staining  was
performed on slides from at least three animals per condition.
Sections were examined by fluorescence microscopy (Zeiss)
and  images  were  false-colored  using  Adobe®  Photoshop
(Adobe Systems, San Jose, CA).
Activity  assay—PLA2G7  is  known  to  catalyze  the
hydrolysis of the substrate platelet-activating factor (PAF)
into the biologically inactive lyso-PAF. The assay (Cayman
Chemical, Ann Arbor, MI) uses 2-thio PAF as a substrate for
PAF-AH. Hydrolysis produces free thiols, reacting it with an
excess of 5,5‘-dithio-bis-2-nitrobenzoic acid (DTNB); which
is measured spectrometrically. Neither the substrate nor the
lyso-PAF react with DTNB. As a negative control the enzyme
source (plasma or retina) is heat-inactivated for 15 min and
used with the substrates; human PLA2G7 provided in the kit
was taken as positive control for all the measurements. The
commercial kit was used according to the manufacturer’s
recommendations.
For tissue levels, retinas were dissected out from eyes of
rd1 (P10), rd2 (P21), and 48 h light-damaged BALB/c mice
and  corresponding  control  animals.  Retinas  were
homogenized in 100 μl of cold Tris-Cl buffer (0.1 M, pH 7.2)
and centrifuged at 10,000x g for 15 min at 4 ºC. Supernatants
were  collected  and  total  protein  content  in  each  sample
assayed by the Bradford method. To determine plasma levels,
blood was collected from the submandibular vein in isoflurane
anesthetized mice. The vein was punctured with a 22 gauge
needle, which initiates blood flow and sample collected with
a  pipette  using  citrate  as  an  anticoagulant  (0.38%  final
concentration).  Plasma  samples  were  collected  after
centrifugation (800x g for 10 min at 4 ºC).
The assay-mixtures each contained 10 μl of sample, to
which 5 μl of assay buffer was added to each well of a 96 well
flat-bottom  plate.  Reaction  in  each  well  was  initiated  by
adding 200 μl of substrate solution (2-thio PAF). Following
incubation at room temperature (30 min for retina, 1 min for
plasma),  10  μl  of  DTNB  was  added  to  each  well.  Color
development was measured in a spectrophotometer (Softmax;
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the  addition  of  DTNB.  Specific  activity  of  PLA2G7  was
calculated from the absorbance values (extinction coefficient
for DTNB at 405 nm, 12.8/mM/cm). Data are expressed as
mean±SE  of  at  least  three  independent  Pla2g7  activity
measurements in units of specific activity for tissue [μmol/
minute/mg of protein] or plasma [μmol/minute/ml of plasma].
RESULTS
Identification  of  candidate  genes:  The  RetNet  database
currently  lists  191  retina-specific  human  loci:  140  of  the
human  disease  loci  are  mapped  and  the  disease  gene
identified, leaving 51 of the human loci uncharacterized (see
RetNet). By correlating the nucleotide position data for each
of these unknown locations with those of the 12489 genes and
ESTs present on the MGU74Av2 array and their orthologs,
we have the potential to identify candidate genes for 37 of
these unsolved disease loci (approximately 73%).
Mapped but unidentified chromosomal disease loci are
typically large, some spanning many cM, and harbor upwards
of hundreds of genes. For example, the 37 RD loci for which
genes matched in the MGU74Av2 array range in size from 1.8
to 49.2 Mbp (median size: 16.71 Mbp). The average number
of genes contained within a location of 16.71 Mbp is 393.18,
based on an average gene density of 40–45 kb [25]. Identifying
potential  candidates  requires  additional  search  criteria.
Underlying an identification of a mapped locus are genetic
differences influencing the susceptibility to a trait or disease.
Thus, here we argued that these presumed genetic differences
should be reflected in the difference in retinal gene expression
of mice with RD.
To  analyze  differences  in  gene  expression  related  to
photoreceptor  degeneration,  we  selected  three  unrelated
mouse models of photoreceptor dystrophy: the rd1 mouse
(calcium overload) [26]; the rd2 mouse (structural defect due
to a mutation in the disc rim protein peripherin); and constant
light-damage (LD; oxidative stress) [3,5,27]. The rd1 mouse
is considered a model for RP, whereas the rd2 mouse and the
LD  model  are  used  as  models  for  both  RP  and  macular
degeneration. For each mouse model, we determined changes
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TABLE 1. GENES CORRESPONDING TO HUMAN DISEASE LOCI IDENTIFIED BY BEING EITHER COMMONLY UP- OR DOWN-REGULATED IN THREE, INDEPENDENT MOUSE MODELS OF PHOTORECEPTOR
DYSTROPHY.
Affymetrix
gene ID Gene name
Gene
symbol
Mouse
transcript
ID
   Human
ortholog NM
Ortholog
chromosomal
location
    Retinal
degeneration
      locus
160901_at FBJ osteosarcoma oncogene Fos NM_010234 NM_001040059 14q24.3 LCA3
97540_f_at histocompatibility 2, D region locus 1 H2-D1 NM_001025208 NM_005516 6p21.3 TULP1/RP14
101923_at
phospholipase A2 group VII (platelet-
activating factor acetylhydrolase, plasma)
Pla2g7 NM_013737 NM_005084 6p21.2-p12
RDS/RP7; GUCA1A,
GUCA1B; BCMAD
98549_at vitronectin Vtn NM_011707 NM_000638 17q11 UNC119/HRG4
98579_at early growth response 1 Egr1 NM_007913 NM_001964 5q31.1 BSMD, PDE6A
92223_at
complement component 1, q subcomponent,
C chain
C1qc NM_007574 NM_172369 1p36.11 NRL/RP27
96020_at
complement component 1, q subcomponent,
beta polypeptide
C1qb NM_009777 NM_000491 1p36.3-p34.1 LCA9, RP32
103033_at complement component 4 (within H-2S) C4 NM_009780 NM_000592 6p21.3 TULP1/RP14
98472_at histocompatibility 2, T region locus 23 H2-T23 NM_010398 NM_005252 6p21.3 TULP1/RP14
94701_at
phosphodiesterase 6B, cGMP, rod receptor,
beta polypeptide
Pde6b NM_008806 NM_000283 4p16.3 PDE6B/CSNB3, MCDR2
102612_at neural retina leucine zipper gene Nrl NM_015810 NM_006177 14q11.1-q11.2 NRL/RP27
160894_at
CCAAT/enhancer binding protein (C/EBP),
delta
Cebpd NM_007679 NM_005195 8p11.2-p11.1 CORD9
94854_g_at guanine nucleotide binding protein, beta 1 Gnb1 NM_008142 NM_002074 1p36.3-p34.1 LCA9, RP32, RD4
93120_f_at histocompatibility 2, K region H2-K NM_001001892 NM_002127 6p21.3 TULP1, RP14
98562_at
complement component 1, q subcomponent,
alpha polypeptide
C1qa NM_007572 NM_015991 1p36.3-p34.1 LCA9, RP32
95974_at guanylate nucleotide binding protein 1 Gbp1 NM_008142 NM_002074 1p36.3-p34.1 ABCA4
103202_at guanylate nucleotide binding protein 3 Gbp3 NM_018734 NM_133263 1p22.2 ABCA4
103634_at
interferon dependent positive acting
transcription factor 3 gamma
Isgf3g NM_008394 NM_006084 14q11.2 NRL/RP27
104669_at interferon regulatory factor 7 Irf7 NM_016850 NM_004030 11p15.5 TEAD1/AA/TCF13/ TEF1
99608_at peroxiredoxin 2 Prdx2 NM_011563 NM_005809 19p13.2 R9AP
The highlighted gene symbols (column 3) represent the mapped, but unsolved loci (column 7), the remaining genes localize to
loci that  have already been solved. The genes are documented with respect to the mouse gene name, symbol and mouse transcript
ID (columns 2-4) and their human ortholog (column 5). Column 6 provides information about the chromosomal location of the
human ortholog; column 7 lists the name(s) of the loci. Please note that in some entries in the locus column, there are multiple
names given, meaning that more than one trait resides in that chromosomal location; however these may or may not be related.
Column 1, the Affymetrix Gene ID; and column 3, the gene symbol; represent the common denominators for all Tables in the
manuscript (Table 1 and Table 2) and Appendix 1 and Appendix 2.in gene expression between the experimental animals and
their age-matched controls at two consecutive time points
early in the progression of degeneration. For a given gene to
be  considered  as  a  possible  candidate  or  a  retina-specific
location,  it  had  to  be  significantly  up-  or  downregulated
(p<0.05) with a predefined mean difference in expression
Figure 1. Pla2g7 mRNA and activity levels, analyzing levels from
P10 rd1, P21 rd2, and 48 h light-exposed BALB/c animals and their
respective  age-matched  controls.  A:  Pla2g7  mRNA  levels  were
plotted  from  Appendix  1.  Retina  Pla2g7  mRNA  levels  are
significantly  reduced  in  all  three  genotypes  when  compared  to
controls. Data are expressed as mean±SD of the two arrays analyzed
per  genotype.  B:  Tissue  retina  Pla2g7  levels  as  measured  in  a
calorimetric assay using 2-thio platelet activating factor (PAF) as
substrate,  revealed  that  activity  levels  in  retinas  from  the  three
genotypes correlated well with the respective reduced amount of
mRNA found in the tissue. Data are expressed as mean±SEM of at
least three, independent samples in unit of activity (μmol/min/mg of
protein). C: Plasma Pla2g7 levels measured in mandibular blood
samples revealed that the two genetic mutations (rd1 and rd2) or the
environmental stress (constant light) did not influence systemic,
plasma-derived Pla2g7 activity. Data are expressed as mean±SEM
of at least three independent samples in unit of activity (μmol/min/
mL of plasma). In the graph, red indicates control and blue indicates
experimental. The following abbreviations were used: light-damage
(LD) and not significant (n.s.)
level (≥100) in at least one of the three models. Of the 902
genes that met these criteria, 20 genes were found to have
human  orthologs  that  were  localized  to  human  retinal
degeneration (Table 1). Experimental data regarding gene
expression  levels  and  fold  differences  in  gene  expression
(Appendix  1)  are  provided  in  the  supplemental  material
section. These 20 genes were ranked on two criteria: (a) based
on their probability of falling within a human disease locus by
chance; (b) multiplied by the number of models in which the
genes were differentially expressed. Due to the significant
difference in locus size for the different diseases (i.e., the 20
loci range in size from 1.7 to 60 Mbp), the probability ranged
from 1.9% to 46.9% (Table 2, column 5), with the median
probability of 6.6%.
Gene ontology analysis of identified genes: To gain biologic
understanding from the identified genes found in unsolved
chromosomal  locations  (Table  1),  we  analyzed  their
functional annotations. GO identifications (GO IDs) and GO
terms were retrieved for all significant ontologies (Biologic
Process,  Molecular  Function,  and  Cellular  Compartment).
The GO terms associated with the 20 identified genes were
compared to those of the reference group (all genes present
on  the  array  minus  those  listed  in  Table  1),  determining
significantly over-represented terms and obtaining important
GO terms that describe these differentially regulated genes.
The  significantly  overrepresented  GO  terms  that  were
retrieved  for  the  upregulated  genes  included  the  terms
“defense response,” “immune response,” and “complement
activation,” whereas in the downregulated genes, the terms
identified  the  keywords  “positive  gene  regulation  of
rhodopsin,” “retinal rod cell development,” and “thioredoxin
peroxidase activity” (Appendix 2).
Pla2g7  in  retinal  degeneration:  Pla2g7  (PAF-AH,  Lp-
PLA2), a possible candidate for a dominant form of macular
dystrophy  (BCMAD),  was  selected  for  further  study.
Pla2g7 mRNA levels are significantly down-regulated in P10
rd1  [fold  difference  (lower  bound;  upper  bound)]  [-1.39
(-1.26; -1.54)], P21 rd2 [-4.5 (-3.5; -5.55)] and 48 h of light-
damage in the BALB/c mouse retina [-2.37 (-1.57; -4.7)],
which  is  before  significant  cell  loss  [9]  (see  Figure  1A).
Pla2g7 localization in ocular tissues and PAF-AH activity
levels in plasma and retina tissue were investigated.
Pla2g7 is a gene highly enriched in the mouse retina
according to the Brain Gene Expression Map; in the retina,
Pla2g7 mRNA is present in the outer nuclear layer (ONL) that
contains only the cell bodies with the nuclei of rods and cones
(retina SAGE library) [28]. Immunohistochemistry revealed
labeling in the photoreceptors (Figure 2), in particular the
inner and outer segments, with additional labeling in the outer
and inner plexiform layer, as well as staining of cells in the
inner retina.
Pla2g7 activity was compared in soluble extracts of retina
and in plasma (Figure 1B,C). Serum levels of Pla2g7 activity
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rd2) or environmental insults (LD; Figure 1C). Plasma levels
in the P10, C57BL/6 wild-type mouse were higher than that
obtained at P21, but not different from rd1 at P10 nor rd2 at
P21 ([in μmol/min/ml plasma] P10: wt, 0.093±0.013 versus
rd1,  0.091±0.0058;  P21:  wt,  0.0367±0.00009  versus  rd2,
0.0387±0.0012). Likewise, no difference was identified in
light-damaged  BALB/c  retina  (cyclic  light,  0.0935±0.005
versus  LD,  0.0913±0.006).  When  compared  to  their
respective age-matched controls, Pla2g7 levels were reduced
by ~30% in the rd1 retinas, by ~70% in the rd2 retinas, and
by ~50% in the light-damaged retinas (Table 3). Relative
changes in retina Pla2g7 mRNA levels were a good predictor
of retina cytosolic Pla2g7 activity levels.
DISCUSSION
Comparative  genomics  analysis  to  identify  novel  disease
genes:  RD-causing  mutations  are  found  in  genes  whose
proteins participate typically in one of four mechanisms: outer
segment morphogenesis, cellular metabolism, function of the
retinal  pigment  epithelium,  and  the  photoreceptor  signal
transduction cascade [29]. However, other genes that are not
typical photoreceptor-specific genes have been identified to
have mutations in inherited RD, which include mutations in
components of the alternative complement pathway (part of
the body’s innate immune system) that have been shown to be
associated  with  AMD  [14,16-18].  Hence,  we  used  a
comparative genomics approach to aid in the identification of
potentially novel disease genes.
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TABLE 2. CHARACTERIZATION OF GENES IDENTIFIED AS CANDIDATES FOR HUMAN DISEASE LOCI.
Affymetrix
gene ID
 Gene
symbol
     Mis-
regulation Animal models Probability Score
    ONL:
sage, qRT-
PCR* injury
Bright LD
#
Retina
network
160901_at Fos up rd1/rd2/LD 0.044 15 x* + 1
97540_f_at H2-D1 up rd1/rd2/LD 0.046 15 x 3
101923_at Pla2g7 down rd1/rd2/LD 0.046 15 x 2
98549_at Vtn down rd2/LD 0.019 10 x 2
98579_at Egr1 up rd1/rd2 0.132 6 x* + 1
92223_at C1qc up rd1/rd2 0.143 6 x + + 3
96020_at C1qb up rd1/rd2 0.116 6 _* + 3
103033_at C4 up rd2 0.046 5 ? + + 3
98472_at H2-T23 up rd2 0.046 5 ? + 3
94701_at Pde6b down rd1/rd2 0.179 4 x 2
102612_at Nrl down rd2 0.066 4 x 2
160894_at Cebpd up rd1/rd2/LD 0.238 3 _ + + 1
94854_g_at Gnb1 down rd2/LD 0.135 2 x 2
93120_f_at H2-K up rd2/LD 0.046 2 x + 3
98562_at C1qa down rd2 0.135 1 _ + 3
95974_at Gbp1 down rd2 0.0338 1 ? + na
103202_at Gbp3 down rd2 0.0338 1 x na
103634_at Isgf3g up rd2 0.066 1 x + 3
104669_at Irf7 down rd2 0.0611 1 _ + 3
99608_at Prdx2 down rd2 0.4691 1 ? na
Genes are identified by Affymetrix Gene ID (column 1) and gene symbol (column 2) for easy comparison with Table 1. Column
3 identifies the type of misregulation (up- or down-regulated) and column 4 documents in which animal models the misregulation
occurs. The probability of each gene to fall within the respective locus is listed in column 5; this probability multiplied by the
number of models in which the genes are differentially expressed (3, 2, or 1) produced a gene ranking score (maximum column
6). The remaining columns document whether the respective gene is present in photoreceptors based on the retina SAGE library
(column 7: x, present; -, absent; ?, no data available; *confirmed by qRT-PCR [9]), whether the gene is misregulated in retina
injury models (column 8; identified by +) or after bright light exposure (column 9; identified by +), or which genes were found
to cluster together (eye database at Genenetwork; column 10; 3 clusters, 1-3 were identified, as well as three unclustered genes).
TABLE 3. ENZYME ACTIVITY FOR PLA2G7 IN RETINAL DEGENERATION
Genotype
treatment
Control Experimental p-value
rd1 0.2753±0.01 0.1953±0.006 <0.01
rd2 0.0805±0.0035 0.027±0.0.0032 <0.001
light damage 0.123±0.015 0.059±0.0012 <0.001
Quantification of specific activity of Pla2g7 [μmol/minute/mg
of  protein] in retina extracts collected from P10 rd1, P21
rd2 mice, and 3-month old BALB/c mice after 24 h of light
damage (column 2), together with their age-matched controls
(column  3).  Cytosolic  levels  of  Pla2g7  were  significantly
reduced  (column  4)  in  all  three  models  of  photoreceptor
degeneration.  Data  is  expressed  as  mean±SEM  for  3-5
samples per condition.Herein we have used gene expression analysis in three
independent  models  of  photoreceptor  dystrophy,  which
showed key pathologies also seen in the human conditions, to
identify novel candidates for gene loci known to be associated
with  inherited  retinal  diseases.  While  it  would  have  been
beneficial to obtain retina-specific arrays for our analysis, the
U74Av2 arrays used had a present rate (i.e., genes that are
expressed in the retina) of >50%, representing >6000 genes/
ESTs. These 6,000 elements cover an estimated 50% of the
13k mammalian retinal transcriptome, as defined by Schulz
and  colleagues  [30]  or  approximately  62%  of  the  mouse
retinal transcriptome identified by Blackshaw and coworkers
[28]. Thus, our proposed “fishing expedition” still presents
tremendous advantages when compared with a hypothesis-
driven data analysis that investigates one gene at a time, but
will likely miss roughly 50% of potential candidates.
To identify novel genes, we carefully filtered the genes
that  matched  human  RD  loci  to  eliminate  false  positives,
resulting in 20 potential gene candidates. These genes were
ranked to focus on genes that have a low probability of falling
within a region of interest by chance. To corroborate the
potential  for  these  20  identified  genes  to  be  part  of  the
molecular signature of photoreceptors and potentially prime
candidate genes for human disease, the genes were further
characterized  based  on  their  known  retinal  expression
patterns.  First,  the  list  of  genes  was  entered  into  the  eye
database at Genework to determine which genes would be
correlated based on gene expression in the eye, within the
BXD strains of mice along with the mouse diversity panel.
Three subnetworks were identified (Table 2, column 10); a
photoreceptor-specific network (Pla2g7, Gnb1, Pde6β, Vtn,
and Nrl), transcription factors (Fos, Egr1, and Cebpδ), and
one specific for immune-response (H2-D2, C1qβ, C1qc, H2-
K,  C1qα, C4,  H2-T23,  Isgf3g, and  Irf7), as well as three
unassociated  genes  (Gbp1,  Gbp3,  and  Prdx2).  Second,  to
determine whether these genes were expressed in the normal
photoreceptors, we examined whether they were expressed in
the  outer  nuclear  layer  (rods  and  cones)  as  assessed  by
Blackshaw and colleagues [28] using a mouse retina SAGE
library or our own quantitative RT–PCR data on mouse ONL
[9] (Table 2, column 7). All but one of the genes that were
identified in at least two out of three models were found to be
present in the photoreceptors, for a total of 13 out of 20. Three
out of 20 genes were found to be absent, and no information
was available for the remaining four out of 20 genes. Third,
this set of 20 genes was compared with genes identified to be
misregulated under unique retinal injury conditions such as
diabetes [32], ischemia-reperfusion injury [33], retinal tears
[34],  elevation  of  intraocular  pressure  [35],  laser-induced
injury  [36],  photoreceptor  degeneration  induced  by  a
photoreceptor-specific cadherin knockout [37], as well as a
model of bright-light damage [37] (Table 2, columns 8 and 9).
As  expected,  more  extensive  overlap  was  observed  with
bright-light-damage-induced genes, as one of our models was
the  constant,  low-light-induced  photoreceptor  cell  death
model (C1qα, C4, Gbp1, H2-K1, H2-T2B, Irf7, Isgf3g, and
Nrl); however, few genes were found to overlap with the
general  retinal  injury  models  (diabetes:  none;  ischemia-
reperfusion injury: none; retinal tears: Egr1, Fos, C1qβ, and
Cebpδ; elevation of intraocular pressure: Egr1, Cebpδ; laser-
Figure  2.  Pla2g7  localization.
Immunohistochemistry was performed
in  juvenile  C57BL/6  (P17)  frozen
sections (A), using no primary antibody
conditions as the negative control (B).
Pla2g7  was  found  to  be  localized
throughout  the  retina.  Relatively
elevated  levels  were  found  in  the
photoreceptor inner and outer segments,
whereas moderate staining was found in
the two plexiform layers, as well as the
inner nuclear layer (INL) and the retinal
ganglion  cell  (RGC)  layer.  For  each
image, the corresponding DIC image is
provided. The following abbreviations
were used: retinal pigment epithelium
(RPE),  outer  segments  (OS),  inner
segments  (IS),  outer  nuclear  layer
(ONL),  outer  plexiform  layer  (OPL),
inner  nuclear  layer  (INL),  inner
plexiform layer (IPL), and RGC: retinal
ganglion cells (RGC). Scale bar in (A)
represents 20 μm.
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knockout  (C4  and  Cebpδ).  Thus,  it  appears  that  the
transcription factors Fos, Egr1, and Cebpδ are induced during
general retinal injury, as is the complement system (C4 and
C1qβ). In summary, the final list of genes should have a high
potential of detecting photoreceptor-specific disease genes.
Candidate genes for retinal disease: Twenty genes passed our
stringent selection criteria. Two out of the 20 genes confirmed
monogenic loci associated with photoreceptor degeneration,
which are typically named for the one gene carrying mutations
responsible for disease (i.e., NRL and PDE6B), demonstrating
that our method is able to identify previously characterized
human retinal disease genes, and thus confirming the validity
of  our  approach.  Fourteen  genes  were  identified  that  fell
within the boundaries of the monogenic locus for which the
responsible gene has already been identified, and are thus
considered  innocent  bystanders:  Locus  (identified  gene)
TULP1 (H2-D1, H2-K, C4, H2-T23), RDS/RP7 (Pla2g7);
GUCA1A  (Pla2g7),  GUCA1B  (Pla2g7),  NRL  (C1qc  and
Isgf3g), UNC119 (Vtn), PDE6A (Egr1), MCDR2 (Pde6β),
ABCA4 (Gbp1 and Gbp3), R9AP (Prdx2), TEAD1 (Irf7). The
eight remaining genes are potential candidates for mapped
disease loci (Table 1). After subtracting those genes that were
determined to be injury-related genes (Fos, C1qβ, Cebpδ, and
Egr1), four potential genes remained. One of those genes was
differentially expressed in three models (Pla2g7), two genes
in two models (C1qc and Gnb1), and one additional gene
(C1qα) was expressed in one of our models (rd2) and the
bright-light-damage model [37]. These four genes are further
discussed immediately below.
PLA2G7 (phospholipase A2, group VII), the top-ranked
gene, is localized within the BCMAD locus, a dominant form
of macular dystrophy. Pla2g7, which is expressed specifically
in  mouse  photoreceptors,  was  downregulated  in  all  three
mouse models of RD. One activity of the enzyme PLA2G7 is
to hydrolyze oxidized phospholipids, which are known to be
generated in photoreceptors during normal light exposure.
Deficiency of plasma PLA2G7 has been shown to increase the
risk of vascular disease due to its antiinflammatory properties,
and its ability to control levels of oxidative stress and lipid
peroxidation [7]. Variants in PLA2G7 have also be found to
be  associated  with  the  risk  of  asthma  [38].  Three
nonsynonymous polymorphisms appear to be associated with
disease, the R92H, A379V, and I198T variants [39]. All three
have decreased substrate affinity of PAF, which could prolong
the half-life of this highly inflammatory protein [38]. Herein,
we found that tissue and plasma levels of Pla2g7 might be
differentially  regulated;  retinal  degeneration  was  only
associated with tissue, but not plasma levels of this enzyme.
In a parallel study, we have confirmed that plasma levels of
PLA2G7 appear not to be associated with a higher risk of
AMD, as assessed in a population of the Rotterdam study
[40].
GNB1 (guanine nucleotide binding protein, beta 1), the
beta-subunit of rod-specific transducin, is localized to the
LCA9 and RP32 loci. RP32, a locus for autosomal recessive
retinitis pigmentosa, is located between 1p13.3 and 1p21.2,
and marks a severe version of RP [41]. The LCA9 locus
involved in autosomal recessive Leber congenital amaurosis,
has been mapped to 1p36 by linkage mapping [42]. Gao and
colleagues have recently reported an association of GNB1
intronic  variants  with  autosomal  recessive  RP,  as  well  as
autosomal recessive cone-rod dystrophy [43]. On the other
hand, Kitamura and colleagues have identified the Gnb1 gene
as the site of mutation responsible for autosomal dominant
Rd4, and have demonstrated that haploinsufficiency is the
cause of disease [44]. This would tend to rule out GNB1 as the
gene responsible for autosomal recessive LAC9 and RP32.
Complement component 1, q subcomponent, alpha and c
polypeptides  (C1qα  and  C1qc),  which  are  upregulated  in
retinal degeneration, are also localized to the LCA9 and RP32
loci. C1qα and C1qc are part of the complement component
C1q, which is an element of the classical complement pathway
of innate immunity. The complement pathway is one of the
major means by which the body recognizes foreign antigens
and pathogens as well as tissue injury, ischemia, apoptosis,
and  necrosis  (reviewed  in  [45]).  However,  in  addition  to
important roles in normal host responses to self and foreign
antigens, the complement system is increasingly recognized
to  be  causally  involved  in  tissue  injury  during  ischemic,
inflammatory and autoimmune diseases (reviewed in [46]).
Recent  genetic  evidence  has  identified  variations  in  the
complement inhibitory protein factor H (also known as CFH)
[14,16-18], as well as variations in the genes for complement
factor B, C2, and C3 [17,47], as major risk factors for the
disease.  However,  it  is  unclear  how  misregulation  of  the
complement system leads to the observed pathology. In mouse
models of retinal disease, eliminating C1qα neither alters the
course of photoreceptor degeneration in the rd1 mouse [48],
nor changes the development of choroidal neovascularization
triggered by laser photocoagulation of Bruch’s membrane
[49].
Conclusion: We have shown that the comparative genomics
approach verified existing RD genes as well as identified
novel RD candidate genes. This approach may be useful for
focusing the search for novel genes in both RD and other
diseases  for  which  there  are  appropriate  mouse  animal
models.  Further  studies  are  now  needed  to  provide  more
evidence of the functionality, role, and relevance of these
genes. Those studies should include sequencing of the human
genes in patients with the appropriate diagnosis as well as the
generation  of  appropriate  knockout  mouse  strains,  or
elimination/activation of the targeted gene or pathway by
pharmacological or molecular means. We hope to test these
and other hypotheses that were generated in an unbiased and
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1646rational  strategy  that  we  systematically  developed  in  this
report.
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Appendix 1: Experimental data on which the selection of genes listed in
Table 1 of the manuscript is based.
A: Gene expression data for genes that are differentially
regulated in the three mouse models of retinal dystrophy—
rd1 mouse, rd2 mouse, and light-damage (LD) in the albino
mouse—as identified by DChip analysis. Gene expression
data  for  the  experimental  and  control  group  at  the  two
experimental time points are listed as follows: columns 2–5
rd1 mouse at postnatal days 6 and 10 (P6, P10); columns 8–
11 rd2 mouse, P14, and P21; and columns 14–17 BALB/c
control and BALB/c LD at 24 h and 48 h of LD. Each value
represents the average of two replicates. B: Differences in
gene expression levels (fold change) and respective difference
of the mean (Δ mean) between experimental retinas and their
age-matched  controls.  Rd1  retinas  were  analyzed  from
postnatal day (P) P6, P10], rd2 retinas from P14, P21, and
light-damaged retinas (LD) after 24 and 48 h of light exposure.
Gene  expression  analysis  contains  procedures  for  strong
control of false discovery rate (FDR). As indicated in the
legend to Table 1, the Affymetrix Gene ID and the gene
symbol  represents  the  common  denominator  for  table
identification in Table 1 and Table 2 as well as Appendix 1,
and Appendix 2.
Appendix 2: Gene ontology analysis for differentially regulated genes found
in unsolved locations.
Gene  ontology  terms  that  are  associated  with  the
differentially  regulated  genes  found  in  unsolved  locations
(tabulated in Table 1-i.e., experimental list) were analyzed.
Over-represented terms for the biologic processes describing
these identified genes were determined by comparing them
with the reference genes (i.e., all the genes present on the
entire  array  minus  the  experimental  list).  The  top  GO
identifications (GO ID; column 1) and GO terms (column 2)
are  listed  to  characterize  as  many  genes  possible  with
significant GO terms. The genes represented by those GO
terms  (column  3),  as  well  as  the  corresponding  p-values
(column 4) are listed.
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